title: The role of advanced glycation end products in the development of atherosclerosis.
abstract: Cardiovascular disease (CVD) is the leading cause of mortality worldwide. Atherosclerosis constitutes the main pattern of cardiovascular disease and leads to thickening of the intima with plaque formation and eventual occlusion of the arterial lumen. A large amount of evidence links advanced glycation end products (AGEs) with the development or progression of atherosclerosis, regardless of the diabetic status. AGEs are a heterogenous group of compounds formed by the nonenzymatic reaction of reducing sugars with proteins, lipids, and nucleic acids. Although AGEs are formed endogenously in the body, diet has recently been recognized as an important exogenous source. An increased understanding of the mechanisms of formation and interaction of AGEs has allowed the development of several potential anti-AGE approaches.
authors.affiliation: Division of Experimental Diabetes and Aging, The Mount Sinai School of Medicine, One Gustave Levy Place, Box 1640, New York, NY 10029, USA. helen.vlassara@mssm.edu
authors.forename: Melpomeni
authors.initials: M
authors.lastname: Peppa
authors.forename: Jaime
authors.initials: J
authors.lastname: Uribarri
authors.forename: Helen
authors.initials: H
authors.lastname: Vlassara
mesh_terms: D000818:Animals; D001161:Arteriosclerosis / Q000209:etiology* / Q000517:prevention & control; D004032:Diet; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006801:Humans
chemical_list: D017127:Glycation End Products, Advanced